While targeting the PD-1/PD-L1 checkpoint has shown promise in a variety of cancers, including renal cell carcinoma, melanoma, and non-small cell lung cancer, prostate cancer, presents unique challenges due to its immunologically “cold” tumor microenvironment (Cha et al., 2019). Here, CD274 is linked to cancer.